Jakinibs for the Treatment of Immunodysregulation in Patients with Gain of Function STAT1 or STAT3 Mutations

Publication date: Available online 6 August 2018

Source: Journal of Allergy and Clinical Immunology

Author(s): Lisa R. Forbes, Tiphanie P. Vogel, Megan A. Cooper, Johana Castro-Wagner, Edith Schussler, Katja G. Weinacht, Ashley S. Plant, Helen C. Su, Eric J. Allenspach, Mary Slatter, Mario Abinun, Desa Lilic, Charlotte Cunningham-Rundles, Olive Eckstein, Peter Olbrich, R. Paul Guillerman, Niraj C. Patel, Yesim Y. Demirdag, Christa Zerbe, Alexandra F. Freeman

Brief Summary

Treatment of the autoimmune and immune-dysregulatory features of patients with STAT1 GOF or STAT3 GOF disease remains challenging. Jakinibs have been used to treat the severe immune-dysregulation in patients with either STAT1 GOF or STAT3 GOF mutations.

https://ift.tt/2M0lPjW